MLC601 in vascular dementia: An efficacy and safety pilot study
Neuropsychiatric Disease and Treatment Oct 12, 2017
Pakdaman H, et al. - The efficacy and safety of MLC601 in the treatment of vascular dementia (VaD) were examined. In comparison with patients treated with placebo, those treated with MLC601 over the 2 years demonstrated dramatically better cognitive outcome. There were no serious adverse events and MLC601 was well-tolerated.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
